ResearchMay 6, 20260 views

Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide.

Semaglutide is best known for its metabolic effects in type-2 diabetes, but new research out of Cambridge just went deeper. This team wanted to see if diabetes—and semaglutide specifically—changes how people decide to put in effort for rewards. Think: how much work are you willing to do for a payoff, and does metabolic health mess with that drive?

P

Neuropsychopharmacology

by Mehrhof SZ, Fleming H, Nord CL

Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide. Mehrhof SZ(1), Fleming H(2), Nord CL(2)(3). Author information: (1)MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK. sara.mehrhof@mrc-cbu.cam.ac.uk. (2)MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK. (3)Department of Psychiatry, University of Cambridge, Cambridge, UK. Motivation plays a fundamental role in human behaviour. Dopaminergic pathways have long been implicated in individual differences in motivation. Emerging evidence suggests such neural mechanisms interact with metabolic processes to coordinate energy expenditure with energy resources, thereby linking motivation with metabolic health. We ask whether a cognitive-computational index of motivation-reliably linked to neuropsychiatric symptoms-is altered in the context of type-2 diabetes and treatment with a GLP-1 agonist (semaglutide). In a pre-registered experiment, we quantified computational effort-based decision-making parameters in participants with diabetes on (N = 58) or off (N = 54) semaglutide treatment, compared to two groups of matched controls without diabetes (N = 58 each). Subjects with type-2 diabetes showed a blunted acceptance bias, a computational parameter describing the bias to accept effort for reward. This effect was not driven by neuropsychiatric comorbidity or antidepressant use. Across all participants, we found that increasing diabetes risk linearly predicted reduced acceptance bias. Participants with diabetes treated with semaglutide did not show restored motivation. Metabolic ill-health is associated with reduced acceptance bias during motivational decision-making. This blunting mirrors-but is largely independent of-neuropsychiatric motivational deficits. This suggests metabolic ill-health is accompanied by a cognitive shift towards energy conservation, potentially contributing to comorbidity between metabolic ill-health and mental illness. © 2026. The Author(s). Conflict of interest statement: Competing interests: The authors declare no competing interests.

Researchers split participants into four groups: people with diabetes on semaglutide, people with diabetes off the peptide, and two control groups without diabetes. They used computational models to break down decision-making around effort and reward—what they call “acceptance bias.” That’s the tendency to say yes to hard tasks, if there’s a reward at stake.

Here’s what they found:

Diabetes blunted the acceptance bias. People with type-2 diabetes were less likely to take on effortful tasks for rewards.

This wasn’t explained by neuropsychiatric symptoms or antidepressant use.

Higher diabetes risk meant lower acceptance bias, in a straight line.

Here’s the kicker: semaglutide didn’t boost motivation in this context. People on the peptide didn’t show restored willingness to put in effort for rewards.

The message: metabolic ill-health shifts the brain toward conserving energy. It’s a cognitive change, not just a mood one, and it’s mostly independent from classic neuropsychiatric motivation issues.

Why does this matter for the research peptide community? If you’re working with semaglutide or other GLP-1 agonists, this is a reminder that metabolic state interacts with cognition in complex ways. There’s a lot more to explore on how these peptides influence not just the body, but also the brain’s motivational circuits.

Want to dig deeper into metabolic peptides or source compounds for your own studies? Check out our vendor directory for vetted peptide suppliers. More research like this keeps the field moving forward.

For Research Use Only

All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.